mavorixafor
mavorixafor is listed in the FDA National Drug Code directory with 1 NDC code, marketed under brand name including XOLREMDI. Available dosage form: capsule, gelatin coated.
Drug Details
- Generic Name
- mavorixafor
- Brand Names
- XOLREMDI
- Application Number
- NDA218709
- Sponsor
- X4 Pharmaceuticals, Inc.
- NDC Codes
- 1
- Dosage Forms
- CAPSULE, GELATIN COATED
- Routes
- ORAL
- Active Ingredients
- MAVORIXAFOR
Indications and Usage
1 INDICATIONS AND USAGE XOLREMDI is indicated in patients 12 years of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lympocytes. XOLREMDI is a CXC chemokine receptor 4 antagonist indicated in patients 12 years of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes. ( 1 )